Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA269272)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32CA236183)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA014236)
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 26 February 2025
First Online: 6 March 2025
Competing interests
: C.M.C. is co-Founder of Merlon Inc, a member of the External Advisory Board for the University of Colorado Cancer Center, has a cross appointment with Duke-NUS, is ex-officio of the executive team for the Cancer Biology Training Consortium, has previously consulted for the Guidepoint Network in an ad hoc fashion, and received licensing reimbursement from Humacyte Inc. None of these relationships provided salary or research support, nor did they play a role in the study design, data collection, data analysis, or decision to publish for this project. The remaining authors have no conflicts to disclose.
